Soluble Neural-cadherin as a novel biomarker for malignant bone and soft tissue tumors

BMC Cancer

Rui Niimi²  Akihiko Matsumine²  Takahiro Iino²  Shigeto Nakazora²  Tomoki Nakamura²  Atsumasa Uchida¹  Akihiro Sudo² 

[1] Mie University, Tsu, Japan

[2] Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu, Japan

关键词: Biomarker;    Shedding;    Prognosis;    Cadherin;    Sarcoma;   

Others  :  1079681
DOI  :  10.1186/1471-2407-13-309

 received in 2012-08-29, accepted in 2013-06-14,  发布年份 2013

【 摘 要 】

Background

Neural-cadherin (N-cadherin) is one of the most important molecules involved in tissue morphogenesis, wound healing, and the maintenance of tissue integrity. Recently, the cleavage of N-cadherin has become a focus of attention in the field of cancer biology. Cadherin and their ectodomain proteolytic shedding play important roles during cancer progression. The aims of this study are to investigate the serum soluble N-cadherin (sN-CAD) levels in patients with malignant bone and soft tissue tumors, and to evaluate the prognostic significance of the sN-CAD levels.

Methods

We examined the level of serum sN-CAD using an ELISA in 80 malignant bone and soft tissue tumors (bone sarcoma, n = 23; soft tissue sarcoma, n = 50; metastatic cancer, n = 7) and 87 normal controls. The mean age of the patients was 51 years (range, 10–85 years) and the mean follow-up period was 43 months (range, 1–115 months).

Results

The median serum sN-CAD level was 1,267 ng/ml (range, 135–2,860 ng/ml) in all patients. The mean serum sN-CAD level was 1,269 ng/ml (range, 360–2,860 ng/ml) in sarcoma patients, otherwise 1,246 ng/ml (range, 135–2,140 ng/ml) in cancer patients. The sN-CAD levels in patient were higher than those found in the controls, who had a median serum level of 108 ng/ml (range, 0–540 ng/ml). The patients with tumors larger than 5 cm had higher serum sN-CAD levels than the patients with tumors smaller than 5 cm. The histological grade in the patients with higher serum sN-CAD levels was higher than that in the patients with lower serum sN-CAD levels. A univariate analysis demonstrated that the patients with higher serum sN-CAD levels showed a worse disease-free survival rate, local recurrence-free survival rate, metastasis-free survival rate, and overall survival rate compared to those with lower serum sN-CAD levels. In the multivariate analysis, sN-CAD was an independent factor predicting disease-free survival.

Conclusions

sN-CAD is a biomarker for malignant bone and soft tissue tumors, and a potentially valuable pre-therapeutic prognostic factor in patients with bone and soft tissue sarcoma.

【 授权许可】

   
2013 Niimi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Charalabopoulos K, Gogali A, Dalavaga Y, Daskalopoulos G, Vassiliou M, Bablekos G, Karakosta A, Constantopoulos S: The clinical significance of soluble E-cadherin in nonsmall cell lung cancer. Exp Oncol 2006, 28:83-85.
• [2]Cavallaro U, Schaffhauser B, Christofori G: Cadherins and the tumor progression: is it all in a switch? Cancer Lett 2002, 176:123-128.
• [3]Wheelock MJ, Johnson KR: Cadherins as modulators of cellular phenotype. Ann Rev Cell Dev Biol 2003, 19:207-235.
• [4]Baki L, Marambaud P, Efthimiopoulos S, Georgakopoulos A, Wen P, Cui W, Shioi J, Koo E, Ozawa M, Friedrich VL Jr, Robakis NK: Presenilin-1 binds cytoplasmic epithelial cadherin, inhibits cadherin/p120 association, and regulates stability and function of the cadherin/catenin adhesion complex. Proc Natl Acad Sci USA 2001, 98:2381-2386.
• [5]Jeanes A, Gottardi CJ, Yap AS: Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene 2008, 27:6920-6929.
• [6]Maretzky T, Reiss K, Ludwig A, Buchholz J, Scholz F, Proksch E, De Strooper B, Hartmann D, Saftig P: ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. Proc Natl Acad Sci USA 2005, 102:9182-9187.
• [7]Van Aken E, De Wever O, Da Rocha AS C, Mareel M: Defective E-cadherin/catenin complexes in human cancer. Virchows Arch 2001, 439:725-751.
• [8]Reiss K, Maretzky T, Ludwig A, Tousseyn T, De Strooper B, Hartmann D, Saftig P: ADAM10 cleavage of N-cadherin and regulation of cell-cell adhesion and beta-catenin nuclear signalling. EMBO J 2005, 24:742-752.
• [9]Uemura K, Kuzuya A, Aoyagi N, Ando K, Shimozono Y, Ninomiya H, Shimohama S, Kinoshita A: Amyloid beta inhibits ectodomain shedding of N-cadherin via down-regulation of cell-surface NMDA receptor. Neurosci 2007, 145:5-10.
• [10]Chan AO, Lam SK, Chu KM, Lam CM, Kwok E, Leung SY, Yuen ST, Law SY, Hui WM, Lai KC, Wong CY, Hu HC, Lai CL, Wong J: Soluble E-cadherin is a valid prognostic marker in gastric carcinoma. Gut 2001, 48:808-811.
• [11]Jaggi M, Nazemi T, Abrahams NA, Baker JJ, Galich A, Smith LM, Balaji KC: N-cadherin switching occurs in high Gleason grade prostate cancer. Prostate 2006, 66:193-199.
• [12]Nagi C, Guttman M, Jaffer S, Qiao R, Keren R, Triana A, Li M, Godbold J, Bleiweiss IJ, Hazan RB: N-cadherin expression in breast cancer: correlation with an aggressive histologic variant—invasive micropapillary carcinoma. Breast Cancer Res Treat 2005, 94:225-235.
• [13]Rieger-Christ KM, Cain JW, Braasch JW, Dugan JM, Silverman ML, Bouyounes B, Libertino JA, Summerhayes IC: Expression of classic cadherins type I in urothelial neoplastic progression. Hum Pathol 2001, 32:18-23.
• [14]Tomita K, Van Bokhoven A, Van Leenders GJLH, Ruijter ETG, Jansen CFJ, Bussemakers MJG, Schalken JA: Cadherin switching in human prostate cancer progression. Cancer Res 2000, 60:3650-3654.
• [15]Inwards CY, Unni KK: Classification and grading of bone sarcomas. Hematol Oncol Clin North Am 1995, 9:545-569.
• [16]Guillou L, Coindre JM, Bonichon F, Nguyen BB, Terrier P, Collin F, Vilain MO, Mandard AM, Le Doussal V, Leroux A, Jacquemier J, Duplay H, Sastre-Garau X, Costa J: Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997, 15:350-362.
• [17]Derycke L, De Wever O, Stove V, Vanhoecke B, Delanghe J, Depypere H, Bracke M: Soluble N-cadherin in human biological fluids. Int J Cancer 2006, 119:2895-2900.
• [18]Voulgari A, Pintzas A: Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 2009, 1796:75-90.
• [19]Foroni C, Broggini M, Generali D, Damia G: Epithelial-mesenchymal transition and breast cancer: Role, molecular mechanisms and clinical impact. Cancer Treat Rev 2012, 38:689-697.
• [20]Bailey T, Biddlestone L, Shepherd N, Barr H, Warner P, Jankowski J: Altered cadherin and catenin complexes in the Barrett’s esophagus-dysplasia-adenocarcinoma sequence: Correlation with disease progression and dedifferentiation. Am J Pathol 1998, 152:135-144.
• [21]De Boer CJ, Van Dorst E, Van Krieken H, Jansen-van Rhijn CM, Warnaar SO, Fleuren GJ, Litvinov SV: Changing roles of cadherins and catenins during progression of squamous intraepithelial lesions in the uterine cervix. Am J Pathol 1999, 155:505-515.
• [22]Cho SB, Lee KH, Lee JH, Park SY, Lee WS, Park CH, Kim HS, Choi SK, Rew JS: Expression of E- and N-cadherin and clinicopathology in hepatocellular carcinoma. Pathol Int 2008, 58:635-642.
• [23]Patel IS, Madan P, Getsios S, Bertrand MA, MacCalman CD: Cadherin switching in ovarian cancer progression. Int J Cancer 2003, 106:172-177.
• [24]Laskin WB, Miettinen M: Epithelial-type and neural-type cadherin expression in malignant noncarcinomatous neoplasms with epithelioid features that involve the soft tissues. Arch Pathol Lab Med 2002, 126:425-431.
• [25]Kashima T, Kawaguchi J, Takeshita S, Kuroda M, Takanashi M, Horiuchi H, Imamura T, Ishikawa Y, Ishida T, Mori S, Machinami R, Kudo A: Anomalous cadherin expression in osteosarcoma. Possible relationships to metastasis and morphogenesis. Am J Pathol 1999, 155:1549-1555.
• [26]Arribas J, Bech-Serra JJ, Santiago-Josefat B: ADAMs, cell migration and cancer. Cancer Metastasis Rev 2006, 25:57-68.
• [27]Matsumura S, Demaria S: Up-regulation of the Pro-inflammatory Chemokine CXCL16 is a Common Response of Tumor Cells to Ionizing Radiation. Radiat Res 2010, 173:418-425.
• [28]Benassi MS, Magagnoli G, Ponticelli F, Pazzaglia L, Zanella L, Gamberi G, Ragazzini P, Ferrari C, Mercuri M, Picci P: Tissue and serum loss of metalloproteinase inhibitors in high grade soft tissue sarcomas. Histol Histopathol 2003, 18:1035-1040.
• [29]Ferrari C, Benassi S, Ponticelli F, Gamberi G, Ragazzini P, Pazzaglia L, Balladelli A, Bertoni F, Picci P: Role of MMP-9 and its tissue inhibitor TIMP-1 in human osteosarcoma: findings in 42 patients followed for 1–16 years. Acta Orthop Scand 2004, 75:487-491.
• [30]Berend KR, Toth AP, Harrelson JM, Layfield LJ, Hey LA, Scully SP: Association between ratio of matrix metalloproteinase-1 to tissue inhibitor of metalloproteinase-1 and local recurrence, metastasis, and survival in human chondrosarcoma. J Bone Joint Surg Am 1998, 80:11-17.
• [31]Roebuck MM, Helliwell TR, Chaudhry IH, Kalogrianitis S, Carter S, Kemp GJ, Ritchie DA, Jane MJ, Frostick SP: Matrix metalloproteinase expression is related to angiogenesis and histologic grade in spindle cell soft tissue neoplasms of the extremities. Am J Clin Pathol 2005, 123:405-414.